In breast cancer, Guarneri et al. reported that the loss of HER2 expression was more frequently observed in patients with neoadjuvant chemotherapy without T-mab as compared to that in patients with T-mab containing neoadjuvant chemotherapy [18]. The gene discussed is ERBB2; the disease is breast cancer.